The revolutionary breast cancer drug Trodelvy has been approved for expanded use. 

Medical Oncologist at Mater Hospital, Professor Fran Boyle has discussed the positive impact of this approval.

Trodelvy can be used to treat HR-positive/HER2-negative breast cancer, as an alternative to chemotherapy for people who become resistant to hormone-blocking treatments.

“It’s like a Trojan horse that carries the chemotherapy close to the cancer cells and releases it in that area and … increases the effect of the chemo on the cancer cells, but reduces the damage [on] … other cells in the body”, Professor Boyle explained.

She continued, “So it’s a new concept for giving chemotherapy in a smarter way”.

Hear more highlights from Afternoons with Deborah Knight below: